Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.
- Associated Conditions
- Diabetic Nephropathy, Hypertension
Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
- Conditions
- CKD5 Stage DialysisHeart Failure
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 330
- Registration Number
- NCT05243199
- Locations
- 🇨🇳
Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Conditions
- Renal Insufficiency, ChronicHyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC)Drug: Placebo
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 716
- Registration Number
- NCT05056727
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- SARS-CoV InfectionCovid19
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
A Study to Evaluate ALN-AGT01 in Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT03934307
- Locations
- 🇬🇧
Clinical Trial Site, Manchester, United Kingdom
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03762850
- Locations
- 🇬🇧
Travere Investigational Site, London, United Kingdom
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT03493685
- Locations
- 🇬🇧
Travere Investigational Site, York, United Kingdom
Bariatric Surgery and Pharmacokinetics of Irbesartan
- Conditions
- Obesity, Morbid
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03476603
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
- Conditions
- Type 2 Diabetic Nephropathy
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-10-10
- Target Recruit Count
- 60
- Registration Number
- NCT03147677
- Locations
- 🇨🇳
Hunan Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Hunan Yiyang Central Hospital, Yiyang, Hunan, China
Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease
- Conditions
- Diabetic Kidney Disease
- Interventions
- Drug: Placebo drug that simulates Irbesartan tabletsDrug: HuangKui CapsuleDrug: Placebo drug that simulates HuangKui capsule
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 414
- Registration Number
- NCT03016832
- Locations
- 🇨🇳
Jiangsu Province Hospital of TCM, Nanjing, Jiangsu, China
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 11
- Registration Number
- NCT02842359
- Locations
- 🇰🇷
Korea, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.